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SECRETORY (s) phospholipases A 2 (PLA 2 ; EC 3.1.1.4) are Ca 2ϩ -dependent enzymes that specifically hydrolyze the two-ester bond of 1,2-diacyl-3-sn-phosphoglycerides to give free fatty acids and lysophospholipids, precursors of potent mediators of inflammation. Considered for a long time to exert a merely digestive function, sPLA 2 are found in many mammalian tissues as well as in the venomous fluid of a variety of animals (8) . Two types of sPLA 2 have been identified so far in mammalian circulating fluids [type I pancreatic sPLA 2 (psPLA 2 ) and type II sPLA 2 ], but very little is still known about their physiological role or mechanism of action (5, 21) . In the past years, more and more pieces of evidence have been produced describing biological effects of sPLA 2 challenge on different cellular models in vitro (8, 11, 18) . It has been proposed that many of these effects can be explained by the generation of bioactive lipids consequent to the enzymatic hydrolysis of membrane phospholipids on target cells. Nevertheless, several pharmacological effects of sPLA 2 do not seem to involve their hydrolytic activity (12, 13, 38) . Binding and cross-linking experiments with two phospholipases purified from the venom of taipan snake, OS1 and OS2, allowed Lambeau and colleagues (25, 26) to identify two different sPLA 2 membrane receptor types. Neuronal-type receptor is the preferential target of neurotoxic sPLA 2 , including OS2 and bee venom sPLA 2 (25, 32) . The second type was originally isolated from rabbit skeletal muscle membranes and is therefore referred to as muscular receptor (M type). M-type receptor binds with high affinity various snake venom phospholipases as well as pancreatic and inflammatory sPLA 2 , suggesting that mammalian sPLA 2 are probably natural ligands of this receptor (17, 23) . The identification of receptors for sPLA 2 opens up the possibility that the biological properties of these proteins could be at least partially ascribed to the activation of a receptormediated signal transduction pathway (7, 14, 32) . Many biological effects of type I psPLA 2 can be mimicked by several snake venom type II sPLA 2 , suggesting a common mechanism of action (13, 38) . sPLA 2 receptormediated effects described so far include the stimulation of cell proliferation in several cell types (11) , vascular smooth muscle contraction (41) , and chemokinesis (18) . It is noteworthy that both psPLA 2 and a type II sPLA 2 from Naja naja venom were able to stimulate extracellular matrix invasion by cancer cells, and this was demonstrated to require detectable levels of expression of the high-affinity receptor (22) . To further investigate the role of phospholipase activity in the pathophysiology of sPLA 2 action on target cells, we decided to compare the ability of ammodytin L (AMDL), an enzymatically inactive snake venom type II sPLA 2 , with type I psPLA 2 in inducing cellular response in rat aortic smooth muscle cells (RASMC), which have been previously reported to be reactive to psPLA 2 stimulation (11) . AMDL is a myotoxic component of the venom of the snake Vipera ammodytes. It belongs to the class of snake venom PLA 2 -like proteins, which, on the basis of their primary structure, strongly resemble type II sPLA 2 toxins but are devoid of hydrolytic activity (20, 29) . These proteins possess unique deviations from the classical sequence of active enzymes, including the replacement with Lys or Ser of Asp 49 , a key residue that coordinates a Ca 2ϩ in the active site (44) . AMDL causes a selective and dramatic degeneration of the skeletal muscle in vivo (3), whereas it displays complex pharmacological behavior in vitro (15, 38) . Concentrations of AMDL capable of destroying differentiated myotubes in culture do not affect other cell types like lymphocytes, erythrocytes, and platelets (15) . Interestingly, several cell lines in culture, such as fibroblasts and human neuroblastoma, respond to AMDL challenge by increasing their thymidine incorporation in analogy with the already mentioned proliferative effect of psPLA 2 in vascular smooth muscle cells and synovial cells (1, 38) . This body of evidence together with the strong sequence homology of psPLA 2 and AMDL prompted us to verify the possibility that psPLA 2 and AMDL act through a common signal transduction pathway to assess the role of hydrolytic activity on the proliferative response of psPLA 2 . Our data show that 1) psPLA 2 stimulates cell proliferation and the Na ϩ /H ϩ antiport activity, resulting in an increase of intracellular pH (pH i ), a permissive factor for cell proliferation and 2) the effect of psPLA 2 is fully mimicked by AMDL, indicating that the hydrolytic activity is not a requirement for the proliferative response of psPLA 2 . The effect of psPLA 2 and AMDL on cell proliferation and pH i is elicited through the binding to the same receptor and is inhibited by heparin: the pathophysiological implications of this finding are also discussed.
EXPERIMENTAL PROCEDURES
Materials. AMDL was a gift of Dr. F. Gubensek (Jozef Stefan Institute, Ljubljana, Slovenia) and was purified as described (24 Cell culture. RASMC were prepared from the explants of the thoracic aorta of 15-wk-old male Wistar rats by the method of Ross (36) . Cells were cultivated in 25-mm plastic tissue culture flasks and were grown in DMEM supplemented with 10% FCS, 100 µg/ml streptomycin, and 100 U/ml penicillin in a humidified atmosphere of 5% CO 2 and 95% air at 37°C. RASM cells, harvested one time per week by 0.25% trypsin-0.02% EDTA and refed every other day, were used as confluent monolayers after 6-8 days at passage level 4-9.
Analysis of DNA synthesis. [ 3 H]thymidine incorporation was used to measure the mitogenic response. DNA synthesis experiments were performed by incubating the cell monolayers in the presence of AMDL. After incubation, the cells were pulsed with 1 µCi/ml of [ 3 H]thymidine and incubated for an additional 3 h. After trypsin treatment for 3 min, cells were harvested by centrifugation and treated with 5% TCA at 4°C for 30 min. The TCA-insoluble fraction was resuspended in 0.1% SDS in 200 mM NaOH, and the samples were counted on a liquid scintillation counter (LKB 1500). For cell proliferative assays, cells were seeded and grown in 30-mm dishes in DMEM supplemented as reported above and in the presence or absence of different effectors. For cell counting, cells were harvested every 24 h by trypsinization and centrifugation and then counted in a Thoma chamber. Each experiment was carried out in triplicate.
Fluorescence-activated cell sorter experiments. Cells washed in PBS were centrifuged at 200 g for 5 min. The pellet resuspended in 100 µl PBS was fixed in 70% (vol/vol) ethanol by adding on ice 900 µl of cold (Ϫ20°C) ethanol and was incubated on ice for at least 30 min. After centrifugation, the pellet was washed one time in 1.5 ml PBS at room temperature and resuspended in 1 ml of DNA staining solution (200 µg propidium iodide ϩ 2 mg RNase A in 10 ml of PBS 4 Cl, external Na ϩ was routinely replaced by equimolar choline chloride concentrations to keep the antiport quiescent. Incubation with the fluorescent dye was carried out as follows: cells were washed two times with Na ϩ buffer and were thus considered HCO 3 Ϫ free. Next, cells were incubated in Na ϩ buffer with the fluorescent dye (1 mg/ml in DMSO) at the final concentration of 1 µg BCECF/ml for 30 min at 37°C in the dark. After the incubation, the medium containing the dye was eliminated, and the cells were washed two times with the same buffer. The calibration curve was carried out as reported previously (42) using the nigericin method in a high-potassium medium, with the same composition as the Na ϩ buffer, but equimolar KCl substituted NaCl. The calibration curve was linear in the range of pH 6.5-7.5 (not shown).
Fluorescence was also measured under continuous magnetic stirring at a controlled temperature (37°C) in a PerkinElmer LS-5 luminescence spectrometer equipped with a chart recorder model R 100A, with excitation and emission wavelengths of 500 and 530 nm, using 5-and 10-nm slits, respectively, for the two light pathways.
Fluorescence was also routinely measured at 450 nm excitation (at this wavelength, the fluorescence is proportional to intracellular dye concentration but is relatively pH insensitive), and the value did not change Ͼ10% during the experimental period.
Determination of intrinsic buffering capacity. The total intracellular buffering capacity (␤ t ) is defined as follows
In the nominally HCO 3 Ϫ -free solutions used in this study, the buffering capacity of CO 2 (␤ CO 2 ) was assumed to be negligible, and ␤ t was therefore taken to be equal to the intrinsic buffering capacity (␤ i ). The ␤ i was determined by using the NH 4 ϩ pulse technique, as previously described (34, 35) according to the formula 4 Cl] in the absence of NH 4 Cl was assumed to be zero.
Iodination of PLA 2 . Iodination of psPLA 2 was carried out by using a chloramine T method, as described by Hanasaki and Arita (11) . Briefly, Na 125 I (10 MBq) was added to 10 µg of psPLA 2 in 100 µl of PBS, pH 7.4, and the reaction was initiated by adding 10 µl of chloramine T (2 mg/ml). After 1 min of incubation at room temperature, the reaction was terminated by adding 10 µl of 35 mM ␤-mercaptoethanol. After adding 20 µl of BSA (50 mg/ml) and 20 µl of KI (100 mg/ml), the reaction mixture was loaded on a G-10 column, and 125 I-labeled psPLA 2 was eluted in PBS containing 5 mg/ml BSA. The specific radioactivity obtained was 1,200
Binding experiments. Binding experiments were carried out at 20°C in 300 µl of a buffer consisting of 135 mM NaCl, 5 mM KCl, 0.1 mM CaCl 2 , 10 mM glucose, 20 mM Tris, pH 7.4, and 0.1% BSA. Confluent RASM cells were grown in 24-multiwell (ϳ5 ϫ 10 5 cells/well) culture plates (Corning), and, before the experiments, the cells were washed two times with the above buffer and incubated with the radiolabeled ligand in the presence and absence of unlabeled competitors. Nonspecific binding is defined as the difference between the binding in the presence and absence of 1,500-fold molar excess of unlabeled psPLA 2 . After 1 h, the medium was removed, and cells were rapidly washed two times and then lysed with 20 mM NaOH in 0.1% SDS. Radioactivity was assayed by a gamma counter (5500 gamma; Beckman) with an efficiency of 80%.
RESULTS
RASM cells have been reported to respond to pancreatic psPLA 2 challenge with a substantial increase on proliferation rate over untreated controls (11) . Our experiments show that AMDL, an sPLA 2 -like snake myotoxin, is able to induce an analogous response, even though it does not possess any PLA 2 activity. Pancreatic psPLA 2 was 500 times more effective than AMDL in stimulating cell proliferation, as assessed either by cell count or [ 3 H]thymidine incorporation. RASMC were incubated with increasing concentrations of psPLA 2 or AMDL for 48 h, pulsed with [ 3 H]thymidine, and counted for radioactivity incorporation. Mean values from three independent experiments (cpm ϫ 10 Ϫ3 / well) are reported in Fig. 1 . Both proteins were able to stimulate [ 3 H]thymidine incorporation over a two-log concentration range, although with different EC 50 values (AMDL EC 50 2.5 µg/ml, psPLA 2 EC 50 5 ng/ml). Cell proliferation rates, in treated RASMC and controls, were also measured by direct cell count. As shown in Fig. 2 , in experimental samples, the cell number significantly increases over control values at a concentration of 13 ng/ml for psPLA 2 and 7 µg/ml for AMDL. RASM cells (10 5 /well) were grown in the presence of either AMDL or psPLA 2 , at the above mentioned-concentration, and every 24 h cells were harvested and counted. After a 48-h exposure to sPLA 2 , we found a significant increase in cell number in treated samples. After 96 h, the treated cell number was increased by ϳ50% with respect to the control. In addition, sPLA 2 -treated RASM cells showed reduced confluence-induced growth inhibition.
In nonsyncronized cell cultures, the relative fraction of cells in different stages of the cell cycle is a function of culture proliferation rate. FACScan DNA analysis (Fig.  3) shows that, in control cultures, ϳ63 and 29% of cells were in G 1 and S plus G 2 /M phase, respectively. After 24 h of AMDL (7 µg/ml) treatment, the fraction of cells in S plus G 2 /M phase increased to 41% with compensatory reduction in the number of cells in G 1 phase (48%). Similar results were obtained with psPLA 2 (data not shown).
The role of the growth factors in the mitogenic response of RASMC to psPLA 2 or AMDL stimulation was also investigated. Serum or growth factors are essential for the mitogenic action of sPLA 2 . As indicated (Fig. 4) , in serum-free conditions, sPLA 2 failed to show any proliferative effect on RASMC. The effect of FCS was reproduced by epidermal growth factor (EGF) in a concentration between 10 Ϫ9 and 10 Ϫ7 M and to a lesser extent by high insulin concentrations (10 Ϫ7 to 10 Ϫ6 M; see Fig. 4 ).
The Na ϩ /H ϩ antiport is a plasma membrane protein that exchanges Na ϩ and H ϩ according to concentration gradient. Besides the housekeeping function in the regulation of pH i and cell volume, the Na ϩ /H ϩ antiport is considered to play a regulative role in cell physiology (45) . Many hormones and growth factors have been reported to be able to modulate pH i through activation of the Na ϩ /H ϩ antiport (4, 16, 45) . We investigated whether AMDL and psPLA 2 could behave toward RASM cells as growth factors also in stimulating Na ϩ /H ϩ antiport activity.
Analysis of pH i at steady state indicates that both proteins were able to induce a significant increase in RASMC pH i in a concentration-dependent manner. Maximal activation of Na ϩ /H ϩ exchanger was reached by AMDL at 7-10 µg/ml and by psPLA 2 at 15 ng/ml, with an increase of pH i over the basal value after 15-min incubation time of 0.23 Ϯ 0.03 (mean Ϯ SD; n ϭ 4) for AMDL and 0.18 Ϯ 0.04 (mean Ϯ SD; n ϭ 3) for psPLA 2 (Fig. 5) .
The time course of pH i recording in the presence of AMDL and psPLA 2 at different concentrations together with the effect of the derivative of amiloride [ethylisopropyl amiloride (EIPA); 10 µM], a specific inhibitor of the Na ϩ /H ϩ antiport, are reported in Fig. 6 . To analyze the effect of AMDL (7 µg/ml) and psPLA 2 (15 ng/ml) in conditions of maximal Na ϩ /H ϩ antiport activation, we carried out experiments of acid load with ammonium chloride (20 mM). Both AMDL and psPLA 2 stimulated http://ajpcell.physiology.org/ the Na ϩ /H ϩ antiport, both as to the rate of recovery (Fig. 7A ) and pH set point (Fig. 7B) . Regression lines computed from experimental values reported in Fig. 7B show that both rate of recovery and pH set point in RASMC were increased by sPLA 2 stimulation. The slope of the lines was not significantly different, whereas the intercept with the x-axis was 7.03, 7.13, and 7.17 for the control, AMDL-, and psPLA 2 -treated cells, respectively (Fig. 7B) .
From data reported in Table 1 , the net efflux of acid (i.e., acid extrusion rate, J) can be calculated. J is the product of ␤ and the rate of pH i recovery (36) . In the nominal absence of HCO 3 Ϫ , the ␤ value is the intrinsic buffer power that at pH i 6.8 is 38 Ϯ 9 mM/pH unit (mean Ϯ SD; n ϭ 3), well in agreement with previously published data (16) . J was evaluated as 1,140 ϫ 10 Ϫ4 , 2,145 ϫ 10 Ϫ4 , and 3,300 ϫ 10 Ϫ4 mM/s at pH i 6.8 for control, AMDL-, and psPLA 2 -treated cells, respectively.
Heparin has been shown to exert protective effects toward several PLA 2 and PLA 2 -like myotoxins, and it is also known to interfere with a wide variety of biological proteins (28, 30) . Heparin was able to inhibit the sPLA 2 -mediated increase in thymidine incorporation (Fig. 8) . The data show that the heparin concentration capable of preventing the sPLA 2 activity was three orders of magnitude lower than the concentration required to block AMDL. These data are consistent with the hypothesis that the target of the heparin is the added protein (i.e., psPLA 2 and AMDL) rather than a molecule involved in the binding and/or in the transduction pathway.
The strong similarity between AMDL and psPLA 2 effects on cell growth and pH i appeared to be very puzzling, and we hypothesized that the two proteins may bind to the same receptor. Therefore, binding and competition experiments were carried out by using 125 I-psPLA 2 and increasing AMDL concentrations. Preliminary experiments indicated that maximum binding for the 125 I-psPLA 2 was achieved at 20°C in 120 min and was stable for at least 2 h (not shown). 125 I-psPLA 2 binding at equilibrium to RASM cells gave a straight line, indicating the presence of a single class of binding sites and, from Scatchard analysis, an equilibrium binding constant (K d ) value of 4 nM, well in agreement Values are means Ϯ SD of 3-6 different experiments. AMDL, ammodytin L; psPLA 2 , pancreatic secretory phospholipase A 2 ; RASM, rat aortic smooth muscle. dpH i /dt was measured at intracellular pH (pH i ) 6.8. ⌬pH i ϭ final pH i Ϫ initial pH i ; ␤, buffering power. Proteins were given to the cells at time 0, before the acid load with NH 4 Cl. NH 4 Cl pulse was carried out as reported in the legend to Fig. 7 . dpH i /dt and set point to calculate ⌬pH i were evaluated from the regression line reported in Fig. 7B for control, 7 µg/ml AMDL and 15 ng/ml psPLA 2 . Fig. 8 . Heparin effect on AMDL and psPLA 2 action on RASM cells. RASM cells were briefly incubated with heparin at the indicated concentrations and then stimulated with AMDL (7 µg/ml) or psPLA 2 (13 ng/ml). Cells were pulsed with [ 3 H]thymidine and processed as described in EXPERIMENTAL PROCEDURES. Results are means Ϯ SD of 3 independent experiments carried out in triplicate.
with data reported by Hanasaki and Arita (11) for the same cells. To investigate whether psPLA 2 and AMDL bind to the same receptor in the RASM cells, our first attempt was to study the K d of AMDL to compare its kinetic values with the those observed for psPLA 2 . We failed to obtain reliable values, due to the high level of nonspecific binding showed by this class of proteins. Basic myotoxins seem to possess a very high affinity for negatively charged surfaces, such as plastic for cell culture and glass. For this reason, as a strategy to approach the problem, we decided to perform competition experiments using labeled psPLA 2 and increasing concentrations of AMDL. The relative inhibitory effects of various concentrations of unlabeled psPLA 2 and AMDL on 125 I-psPLA 2 equilibrium binding to RASM cells are shown in Fig. 9A . The concentration of psPLA 2 that inhibits one-half of the 125 I-psPLA 2 specific binding (K 0.5 ) was 10 Ϫ9 M. AMDL also inhibited 125 I-psPLA 2 specific binding to RASM cells but with a K 0.5 more than two orders of magnitude (2 ϫ 10 Ϫ7 M), indicating a difference in affinity between psPLA 2 and AMDL. The same strategy was used to investigate the effect of heparin on the 125 I-psPLA 2 binding to the RASM cells. Figure 9B indicates that heparin prevents 125 I-psPLA 2 binding to the cells in a dose-dependent manner. An apparent K 0.5 was raised at a heparin concentration two to three orders of magnitude higher (molar ratio) than the phospholipase concentration. In these experiments, it is important to take into account that the 125 I-psPLA 2 binding displacement by heparin did not possess the same significance of the data obtained with phospholipases. In fact, heparin likely binds to several ''highaffinity'' binding sites on the surface of the cells, and an exact calculation of its K 0.5 on 125 I-psPLA 2 binding could be artifactual. Our results purely indicate that the heparin able to inhibit the 125 I-psPLA 2 binding to RASM cells is, as expected, close to the concentration that inhibits the physiological effect of phospholipases.
DISCUSSION
This study shows that both psPLA 2 and AMDL can stimulate RASMC proliferation in culture and that this effect is preceded by an increase of pH i , dependent on the activation of the Na ϩ /H ϩ antiport. We propose that the proliferative effect is mediated by the same transduction pathway for both proteins.
To support this statement, we demonstrate that 1) both psPLA 2 and AMDL stimulate thymidine incorporation by RASMC in a dose-dependent manner, although a 500-fold higher AMDL concentration is required to elicit an identical response; 2) AMDL was able to displace the 125 I-PLA 2 from specific binding sites in a concentration range consistent with that capable of eliciting a cellular response; 3) cell growth and FACScan experiments indicate that psPLA 2 and AMDL affect cell cycle control; 4) the presence of FCS and/or growth factors is required by both proteins to exert their stimulatory effect on DNA synthesis; 5) the relative concentrations of psPLA 2 or AMDL necessary for the activation of Na ϩ /H ϩ exchange activity are similar to the concentrations required to stimulate RASM cell proliferation; 6) the time course of the effect of psPLA 2 and AMDL on RASMC pH i is superimposable; and 7) the inhibition by heparin is similar for both proteins, taking into account the ratio of heparin to protein.
Although there is compelling evidence for a central role of sPLA 2 in the pathogenesis of several preinflammatory situations, very little is still known about the molecular details of the cascade of events that follow the interaction of psPLA 2 with target cells (43) . Different cellular models have been reported to react to psPLA 2 stimulation by proliferating, likely via the activation of the mitogen-activated protein kinase cascade (13) . A direct involvement of sPLA 2 in proliferation and migration of RASMC, after arterial injury, appears to be a pivotal clinical problem in the management of atherosclerosis and angiogenesis occurring in response to a variety of physiological or pathophysiological stimuli (46) . Autocrine mechanisms of production of growth factors by RASMC, such as platelet-derived growth factor (PDGF), EGF, and insulin-like growth factor I http://ajpcell.physiology.org/ (IGF-I) acting synergically, are responsible for RASMC proliferation after injury (37) . When RASMC are incubated with proinflammatory cytokines, such as tumor necrosis factor, interleukin-1, or cAMP-elevating agents, gene expression of sPLA 2 is induced, and the newly generated sPLA 2 are found in the extracellular medium (31) .
Because many hydrolysis products of phospholipids by sPLA 2 (i.e., arachidonic acid, lysophosphatidylcholine, and lysophosphatidic acid) are mediators of the inflammatory response, the most obvious model for sPLA 2 action hypothesizes the hydrolysis of plasma membrane phospholipids of target cells and the consequent release of active lipids. Nevertheless, in living cells, plasma membrane phospholipids are a very poor substrate for sPLA 2 , and extensive phospholipid hydrolysis by exogenous sPLA 2 has been described only in microvesicles shed from activated cells and membranes derived from cells undergoing apoptosis (2, 10) .
An intriguing question arises about the role of sPLA 2 enzymatic properties in the activation of this signal transduction pathway. Do sPLA 2 , in the induction of their proliferative response, behave just like receptor ligands, or, upon binding on the receptor, do they hydrolyze cell membrane phospholipids to produce bioactive lipid species? This point is still a matter of debate. Arachidonic acid production has been demonstrated after incubation of cultured cells with sPLA 2 (13) , but the total absence of oleate or unsaturated fatty acid from culture supernatant induced Hernandez et al. (13) to imply the activation of a cytoplasmic phospholipase that, unlike sPLA 2 , is known to be highly selective for arachidonic acid-containing membrane phospholipids.
In this work, we provide evidence that AMDL, a sPLA 2 -like snake toxin that does not possess any hydrolytic activity, is able to trigger a mitogenic response in RASM cells. The fact that phospholipase activity does not seem to be required for sPLA 2 stimulation of mitogenesis strongly supports the hypothesis that sPLA 2 acts as pure ligand by activating a cell membrane receptor. sPLA 2 -like toxins, in this context, are natural sPLA 2 mutants and can represent a valuable tool for unraveling the pharmacological properties of this class of molecules.
Binding experiments on RASM cells have shown that these cells do express an sPLA 2 receptor whose relative molecular mass and sPLA 2 binding affinity indicate that it belongs to the M-type receptor class (11) . A good correlation exists between cell responsiveness and the expression of the M-type receptor for sPLA 2 , a 180-kDa glycoprotein that shows strong homology with the macrophage mannose-binding receptor (5 2 , we suggest that the 500-fold difference between AMDL and sPLA 2 in the relative potency in stimulating RASMC proliferation could be explained as the effect of a 500-fold difference in the binding affinity.
On the basis of our results, the transduction pathway involves an increase in pH i , due to activation of the Na ϩ /H ϩ antiport, a permissive factor for cell proliferation (35) . In fact, both psPLA 2 and AMDL were able to induce an increase in pH i at equilibrium and under conditions of best activation for the antiport, after an acid load with ammonium chloride. The specificity of the effect is assessed by the inhibition of the antiport by the derivative of amiloride, EIPA. The effect on pH i is dose dependent, and ⌬pH i is in the same range as the one reported for hormones and growth factors (35) .
The buffering capacity (␤) and the rate of recovery (dpH i /dt) show only a trend to an increase in psPLA 2 -and AMDL-treated cells, but J, the net efflux acid, increases in treated cells. The increased J, in turn, could activate the Na ϩ /Ca 2ϩ exchanger, due to the http://ajpcell.physiology.org/ increased intracellular Na ϩ , allowing a massive influx of Ca 2ϩ from extracellular medium. In the pathological condition in which sPLA 2 is greatly increased, as in the ischemic condition, this Ca 2ϩ overload could give rise to cell death (9, 27) .
Furthermore, our data show that psPLA 2 are weak mitogens for RASMC but greatly increase the proliferative activity of serum. Both EGF and insulin (at concentration Ͼ10 Ϫ7 M) can substitute for serum as a comitogen factor. RASMC proliferation can be stimulated by a variety of growth factors, and relevant information is available on the synergy between growth factors (37, 46) . For example, weak mitogens such as IGF-I increase the ability of other mitogens such as PDGF, fibroblast growth factor, and EGF (33) , and insulin is an important comitogen for ANG II and EGF (19) . However, the basis of this synergy between growth factors is not well understood. A hypothesis could be that sPLA 2 stimulates the expression of the comitogen receptors or that the increase of intracellular Ca 2ϩ and/or pH amplifies the mitogen effect.
Heparin has been reported to inhibit cell growth and Na ϩ /H ϩ exchange in vascular smooth muscle cells (7) . The fact that heparin inhibits activity of both psPLA 2 -and AMDL-induced cell proliferation to the same extent provides further support for the hypothesis of a common mechanism of action of these two proteins. Our competition experiments on 125 I-psPLA 2 binding clearly show that heparin inhibits the binding of the phospholipase to the RASM cells. It is likely that the inhibitory effect of heparin on psPLA 2 -induced cell growth is due to a direct effect of the glycan on the phospholipase binding and not to the inhibition of its transduction process. This statement is in good agreement with the recent observation that PLA 2 binds, as several growth factors, the cellular matrix of vascular cells and that heparin can prevent this binding (40) . On the basis of our data, we are not able to demonstrate if heparin inhibits the psPLA 2 binding to its receptor by a direct interaction with the phospholipase or with the receptor.
In any case, the relationship between heparin and different classes of PLA 2 is very puzzling. Lomonte et al. (28) have shown that heparin blocks the cytolytic effect of the snake venom myotoxin II, probably through the binding with the fragment 119-125 COOH-terminal. Analogously, recombinant sPLA 2 , lacking a Lys residue in the COOH-terminal, is unable to bind both heparin and cells in culture but retains its hydrolytic activity on artificial phospholipid membranes (30) . The same terminal Lys-mutated sPLA 2 bind preapoptotic cells, which are known to expose acidic phospholipids on the external surface of the plasma membrane. Furthermore, a previous paper from our laboratory has shown that the PLA 2 -like myotoxins can penetrate in the hydrophobic core of artificial bilayers only if acidic lipids are present (39) . Finally, a common pathway between toxic, pancreatic, and secreted PLA 2 seems to be the binding to a ''negatively charged compartment'' on the surface of the cell membrane. Heparin could inhibit the different physiological and pharmacological sPLA 2 effects through the same mechanism. More focused experiments, using purified heparin molecular species, must be carried out to identify the polysaccharide sequence that binds with high affinity to the sPLA 2 . These data could be of enormous interest considering the therapeutic potential of heparin, a drug whose anti-inflammatory and antiatherosclerotic role is so far stated but poorly understood.
